Evidence map›Paper›PMID 39641864›Full record

ArticleAMB Express2024

Omnigene-Gut

Raoull Hoogendijk, Thijs J M van den Broek, Hyunju Lee, Sabine Mueller, Cassie Kline, John Bianco, Janetta Top, Marcel R de Zoete, Lennart Kester, Friso Calkoen and 1 more

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AMB Express, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04732065 phase1recruitingnot on this map

Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

TypeinterventionalSponsorSabine Mueller, MD, PhDRan2021 to 2027Enrolled208ConditionsDiffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Recurrent Malignant Central Nervous System NeoplasmArmsONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS)
NCT04775485 phase2recruitingnot on this map

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

TypeinterventionalSponsorDay One Biopharmaceuticals, Inc.Ran2021 to 2027Enrolled141ConditionsLow-grade Glioma, Advanced Solid TumorArmsTovorafenib
NCT05009992 phase2recruitingnot on this map

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

TypeinterventionalSponsorUniversity of California, San FranciscoRan2021 to 2029Enrolled360ConditionsDiffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-MutantArmsONC201, Radiation Therapy, Paxalisib, DNX-2401
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raoull HoogendijkPrincess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands. r.hoogendijk@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0002-8033-2093
Thijs J M van den BroekPrincess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.
Hyunju LeeDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, 94143, USA.
Sabine MuellerDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, 94143, USA.
Cassie KlineDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.
John BiancoPrincess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.
Janetta TopDepartment of Medical Microbiology, University Medical Center, Utrecht, 3584 CX, Utrecht, The Netherlands.
Marcel R de ZoeteDepartment of Medical Microbiology, University Medical Center, Utrecht, 3584 CX, Utrecht, The Netherlands.
Lennart KesterPrincess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.
Friso CalkoenPrincess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands.
Jasper van der LugtPrincess Máxima Center for Pediatric Oncology, 3584 CS, Utrecht, The Netherlands. j.vanderlugt@prinsesmaximacentrum.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence exists that the gut microbiome influences toxicity as well as outcomes in a variety of cancers. To investigate the role of the gut microbiome in pediatric neuro-oncology, microbiome analysis has been included in multiple prospective pediatric neuro-oncology clinical trials (NCT05009992, NCT04732065, NCT04775485). In these trials, the OMNIgene-GUT

Indexed as

Clinical trialsMicrobiomeNeuro-oncologyPediatricsValidation

Identifiers

PMID39641864
PMCPMC11624167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.